INmune Bio

INmune Bio is pioneering a precision approach to innate immune system modulation, focusing on restoring normal function rather than broad suppression. The company has two late-stage assets with near-term regulatory and pivotal-trial milestones, targeting significant markets in Alzheimer's disease and oncology. Its clinical development strategy emphasizes matching drug mechanism to patient biology and using relevant outcome metrics that prioritize patient benefit.

Platform for selective modulation of innate immune system components, specifically targeting soluble Tumor Necrosis Factor (sTNF) to reduce pathological inflammation and using in vivo priming to activate Natural Killer (NK) cells against cancer.

In Alzheimer's, competes with amyloid/tau-targeting biologics (e.g., Eisai/Biogen) and other neuroinflammation approaches. In oncology, faces competition from approved CAR-T therapies, bispecific antibodies, and other NK cell platforms. Differentiation lies in precise targeting of soluble TNF and in vivo NK cell activation, aiming for better safety and practicality.